A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood (Alfa-PROTECT)

A Phase 3, Single Group Treatment, Open-label, Study to Evaluate the Safety of BAY 94-9027 Infusions for Prophylaxis and Treatment of Bleeding in Previously Treated Children Aged 7 to <12 Years With Severe Hemophilia A

Researchers are looking for a better way to treat hemophilia A. Hemophilia A is a genetic disorder where the body does not create enough of a protein called clotting factor 8 (FVIII) present in the blood. People with hemophilia A may bleed for a long time from minor wounds, have painful bleeding into joints, or have internal bleeding. In severe hemophilia A (clotting factor 8 levels less than 1%) bleedings are more likely to happen.

In this study researchers want to learn more about the treatment called BAY94-9027. BAY94-9027 is an injectable medicine used to replace missing clotting factor 8. In BAY94-9027 the clotting factor 8 has been pegylated (combined with a substance called polyethylene glycol (PEG)). This is to make the treatment last longer in the body so that less injections are required. BAY94-9027 is already available for the prevention and treatment of bleeding in adults and children who are 12 years and older. BAY 94-9027 is also called Jivi.

BAY94-9027 is not yet available for children aged 7 to less than 12 years. One potential specific risk of pegylated drugs is that proteins in the blood called antibodies are built. These may attach to the pegylation part of the drug and this in turn may lead to allergic reactions and the drug not working as well as it should during first 4 infusions. In studies that have been done so far, this has been seen in some children younger than six years, but not in 29 children aged 6 to less than 12 years treated with BAY94-9027. Further safety information related to how the body reacts to BAY94-9027 is however still needed for this age group.

The main purpose of this study is to learn how safe BAY94-9027 is (safety) and how it affects the body (tolerability) in previously treated children with severe hemophilia A who are between 7 to less than 12 years. To answer this question, the researchers will study information about two medical problems of special interest, if allergic reactions occur (also called hypersensitivity) and if the drug is not working as well as it should (also called loss of efficacy) during the first 4 infusions.

Allergic reactions may range from mild local reactions to widespread effects such as shortness of breath, skin rashes and low blood pressure. Only allergic reactions related to the study treatment will be considered.

The assessment if loss of efficacy occurred will be based on the occurrence of bleeding, the clotting factor 8 level in blood after injection called recovery, clotting factor 8 inhibitor tests and measurement of antibodies against the PEG.

The study has two parts, A and B. Part A takes 6 months and part B takes 18 months. In part A the participants will receive two injections of BAY94-9027 per week. In part B, the number of injections may be decreased, with up to five days between the injections. The participants in this study will visit the study site around 14 times and will have 15 phone visits. In part A, visit 1 is for screening. Visits 2 to 5 take place twice a week for two weeks. Visit 6 two weeks after visit 5, visits 7 to 10 take place monthly with visit 11 six weeks after visit 10. In part B, site visits will occur on month 9, 12, 18 and 24 and phone calls every month between the site visits. The participants' and their caregivers will record in an electronic patient diary information about when the study treatment was given and bleeding episodes that have happened.

During the study, the study doctors and their team will

• take blood samples,
• do physical examinations,
• review the participants' electronic diary
• ask questions about the participants' quality of life,
• ask the participants questions about how they are feeling and what adverse events they are having An adverse event is a medical problem that happens during the study. Doctors keep track of all adverse events that happen in study, even if they do not think the adverse events might be related to the study treatments.

Study Overview

• Status: Completed
• Conditions: Hemophilia A; Children; Prophylaxis of Bleeding; Treatment of Bleeding
• Intervention / Treatment: Biological: Damoctocog alfa pegol (Jivi, BAY94-9027)

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires
    • La Plata, Buenos Aires, Argentina, 1900
      • Hospital de Niños Sor María Ludovica
  • Mendoza Province
    • Godoy Cruz, Mendoza Province, Argentina, 5501
      • Instituo Hematología Arbesú
  • Santa Fe Province
    • Rosario, Santa Fe Province, Argentina, S2000CKF
      • Instituto de Hematología Dr. Rubén Dávoli
• Brazil
  • Rio de Janeiro
    • Rio de Janeiro, Rio de Janeiro, Brazil, 20211-030
      • Hemorio
  • São Paulo
    • Campinas, São Paulo, Brazil, 13083-878
      • Hospital das Clínicas de Campinas - UNICAMP
    • Ribeirão Preto, São Paulo, Brazil, 14051-140
      • Hosp Clínicas Facult. Med. de Ribeirão Preto / USP
    • São Paulo, São Paulo, Brazil, 01223-001
      • Irmandadade da Santa Casa de Misericordia de Sao Paulo (iSANTACASA)
• Canada
  • Ontario
    • Hamilton, Ontario, Canada, L8N 3Z5
      • McMaster Children's Hospital
• Italy
  • Lazio
    • Roma (RM), Lazio, Italy, 00165
      • Ospedale Pediatrico Bambino Gesù - Oncoematologia, Trapianto Emopoietico e Terapie Cellulari
• Norway
  • Oslo, Norway, 372
    • OUS Rikshospitalet Klinisk Forskningspost Barn
• Turkey (Türkiye)
  • Adana, Turkey (Türkiye), 01130
    • Acibadem Adana Hastanesi, Çocuk Sagligi ve Hastaliklari, Çocuk Hematoloji-Onkoloji Bölümü
  • Ankara, Turkey (Türkiye), 06230
    • Hacettepe Üniversitesi Tip Fakültesi, Hacettepe Ihsan Dogramaci Çocuk Hastanesi,
  • Antalya, Turkey (Türkiye), 07059
    • Akdeniz Üniversitesi Tip Fakültesi Çocuk Sagligi ve Hastaliklari Anabilim Dali Çocuk Hematoloji ve Onkoloji Bilim Dali
  • Gaziantep, Turkey (Türkiye), 27100
    • Gaziantep Üniversitesi Tip Fakültesi, Sahinbey Arastirma Ve Uygulama Hastanesi, Çocuk Hematoloji ve Onkoloji Bilim Dali
  • Izmir, Turkey (Türkiye), 35100
    • Ege Üniversitesi Tip Fakültesi, Çocuk Sagligi ve Hastaliklari Anabilim Dali, Çocuk Hematoloji Bilim Dali
  • Samsun, Turkey (Türkiye), 55200
    • Ondokuz Mayis Üniversitesi Tip Fakültesi, Saglik Uygulama ve Arastirma Merkezi, Çocuk Sagligi ve Hastaliklari Anabilim Dali
• United States
  • Florida
    • Orlando, Florida, United States, 32806
      • Arnold Palmer Hospital for Children

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 7 years to 11 years (Child)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Participants with severe hemophilia A (participant's own FVIII activity [FVIII:C] <1%)
• Participants must be previously treated with FVIII concentrate(s) (plasma derived or recombinant) for a minimum of 50 exposure days (EDs) at the time of signing the informed consent
• Participant has understood the study if appropriate for his age, informed consent must be signed by the parent, the participant can only sign the assent
• Willingness and ability of participants and/or parents /caregivers to complete training in the use of the electronic patient diary (EPD) and to document infusions during the study

Exclusion Criteria:

• History of FVIII inhibitors
• Current evidence of inhibitor to FVIII measured using the Nijmegen-modified Bethesda assay (≥0.6 BU/mL) at the time of screening (central laboratory)
• Any other inherited or acquired bleeding disorder in addition to hemophilia A (e.g. von Willebrand disease, hemophilia B)
• Known hypersensitivity or allergic reaction to drug substance, excipients or mouse or hamster protein
• Any other significant medical condition that the investigator feels would be a risk to the patient or would impede the study
• Requires any pre-medication to tolerate FVIII treatment (e.g. antihistamines)
• Planned major surgery during the study
• Any individual who is receiving chemotherapy, immune modulatory drugs other than anti-retroviral chemotherapy, or chronic use of oral or intravenous (IV) corticosteroids (> 14 days) within the last 3 months
• Any individual who received commercially available subcutaneous factor substitution therapy (emicizumab) within the last 6 months
• The participant is currently participating in another investigational drug study or has participated in a clinical study involving an investigational drug within 30 days of study entry or previous participation in a clinical study with BAY94-9027

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Main study (Part A) and the extension study (Part B); Part A will last for 6 months. After completing Part A participants will continue in the extension study for another 18 months.

Biological: Damoctocog alfa pegol (Jivi, BAY94-9027); Part A: 40 IU/kg (up to 60 IU/kg at the investigator's discretion), two times per week (2x/week) with the first 4 infusions under medical supervision. Thereafter, participants will continue their treatment as home treatment. Dose may be increased up to 60 IU/kg if needed at any time during the study at the investigator's discretion. Part B: Each participant may continue on prophylaxis dose regimen as prescribed in part A (40 - 60 IU/kg, 2x per week) or adjustments to prophylaxis dose / dose frequency can be made at the investigator's discretion (based on the bleeding events and individual needs): Dose frequency may be decreased to every 5 days with a prophylaxis dose of 60 IU/kg.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Events of Special Interest (AESI) Hypersensitivity and Loss of Efficacy Associated With the First 4 Exposure Days (EDs) Leading to Discontinuation	The occurrence of the defined adverse events of special interest was documented during the first 4 days that a participant was exposed to the study intervention.	Individual first 4 exposure days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse Drug Reactions (ADRs)	Adverse drug reactions were defined as any adverse events where a causal relationship of at least possibly related with the use of BAY 94-9027 had been ascribed by the investigator. In this study, treatment emergent study drug-related adverse events were used in defining ADRs.	Up to 24 months
Anti-drug Antibody (ADA) Development	All participants were tested for the development of anti-drug antibodies (ADAs) (anti-polyethylene glycol [PEG] and anti-PEG immunoglobulin M [IgM]).	Up to 24 months
The Number of Participants With Confirmed Factor VIII Inhibitors	A positive FVIII inhibitor test was defined with a threshold of ≥ 0.6 BU/mL at the central laboratory. The first positive measurement was confirmed by a second, different sample.	Up to 24 months
Annualized Bleeding Rate (ABR)	For each participant, the number of bleeds was related to the individual observation period to assess bleeding rates. For descriptive analyses, bleeding rates were annualized at the individual participant level using the formula: ABR = (number of bleeds × 365.25 × 24 × 60)/(Period). Period was defined as the number of minutes calculated from the date and time of the beginning of the treatment period and the date and time of the end of the treatment period of interest.	Up to 24 months
BAY94-9027 Consumption	Summary statistics for BAY 94-9027 consumption are provided for prophylaxis treatment, for treatment of bleeds, and overall. Consumption per year and per infusion is presented based on total dose (IU) and dose per body weight (IU/kg).	Up to 24 months
Number of Infusions/Month and Year (Annualized Infusion Rate)	Number of infusions per month and year	Up to 24 months

Collaborators and Investigators

• Sponsor: Bayer

Publications and helpful links

General Publications

• Ozelo MC, Luciani M, Glosli H, Kavakli K, Samji N, Makris GC, Tueckmantel C, Enriquez MM, Oliveira LC, Gupta S, Arbesu MG, Davoli M, Chan AKC, Mancuso ME. Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main Study. Eur J Haematol. 2026 Jan 14. doi: 10.1111/ejh.70078. Online ahead of print.
• Ozelo MC, Luciani M, Glosli H, Kavakli K, Samji N, Makris GC, Tueckmantel C, Maas Enriquez M, Oliveira LC, Gupta S, Arbesu MG, Davoli M, Chan AKC, Mancuso ME. Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa-PROTECT Main Study. Eur J Haematol. 2026 Jan 4. doi: 10.1111/ejh.70059. Online ahead of print.

Helpful Links

• Click here to find information on this study on Bayer's website.

Study record dates

Study Major Dates

• Study Start (Actual): March 23, 2022
• Primary Completion (Actual): January 4, 2024
• Study Completion (Actual): June 25, 2025

Study Registration Dates

• First Submitted: November 24, 2021
• First Submitted That Met QC Criteria: December 3, 2021
• First Posted (Actual): December 7, 2021

Study Record Updates

• Last Update Posted (Actual): January 21, 2026
• Last Update Submitted That Met QC Criteria: January 2, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Genetic Diseases, Inborn; Hematologic Diseases; Blood Coagulation Disorders; Hemorrhagic Disorders; Blood Coagulation Disorders, Inherited; Coagulation Protein Disorders; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hemic and Lymphatic Diseases; Hemophilia A; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors; Blood Proteins; Blood Coagulation Factors; Protein Precursors; Factor VIII
• Other Study ID Numbers: 21824; 2021-004858-30 (EudraCT Number); 2023-504388-18-00 (Registry Identifier: CTIS)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: There are no current plans to share data. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Study Data/Documents

1. CTIS Summary of Results
   Information identifier: 2023-504388-18-00
2. Layperson Summary of Results
   Information identifier: 2023-504388-18-00

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No